Drugs / Dendritic Cell Immunization
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00338377 | Feb 2006 → Feb 2030 expected | melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03548571 | Apr 2018 → Dec 2025 | glioblastoma | Oslo University Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic cell immunization | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03548571 ↗ |
| Modality | Vaccine | “the vaccine of dendritic cells” NCT00338377 ↗ |
| Route | Intravenous | “given by vein over 20-30 minutes” NCT00338377 ↗ |